Etanercept — CPB 0315 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0315 governing etanercept (Enbrel) coverage, effective January 5, 2026. Here's what billing teams need to know before submitting claims under HCPCS J1438.

Aetna's etanercept coverage policy under CPB 0315 covers HCPCS J1438 (injection, etanercept, 25 mg) across multiple inflammatory conditions — but the criteria are layered and specific. The January 5, 2026 update tightens prescriber specialty requirements and sets explicit biomarker testing thresholds for rheumatoid arthritis. If your team bills J1438 for RA, psoriatic arthritis, plaque psoriasis, or any of the other covered indications, the updated medical necessity rules now govern every prior authorization request.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Etanercept (Enbrel) — CPB 0315
Policy Code	CPB 0315
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Rheumatology, Dermatology, Oncology, Hematology
Key Action	Audit prior authorization submissions for prescriber specialty and biomarker documentation before January 5, 2026

---

Aetna Etanercept Coverage Criteria and Medical Necessity Requirements 2026

CPB 0315 is Aetna's coverage policy for etanercept (Enbrel), a TNF inhibitor used across a wide range of inflammatory and autoimmune conditions. The January 5, 2026 update restructures medical necessity criteria in two significant ways: prescriber specialty requirements are now explicitly defined by indication, and RA coverage requires documented biomarker testing results.

Prescriber Specialty Requirements

Aetna now requires that etanercept be prescribed by — or in consultation with — a specialist matched to the specific diagnosis. This isn't a general "specialist preferred" standard. It's a hard requirement by indication.

If a primary care physician is managing etanercept without a qualifying specialist's involvement, expect a claim denial. Document the consultation explicitly in the prior authorization submission.

Rheumatoid Arthritis: The Biomarker Gate

The RA criteria are where this update gets operationally complex. Aetna approves etanercept for RA adults through two pathways.

Pathway 1 — Prior biologic or targeted synthetic use: The member has used a biologic or targeted synthetic drug (such as Rinvoq or Xeljanz) for moderately to severely active RA within the past 120 days. This is the simpler path.

Pathway 2 — First-line biologic with step therapy: This requires two documented conditions.

First, biomarker testing. The member must have tested positive for rheumatoid factor (RF, CPT 86430/86431) or anti-CCP (CPT 86200) — or have been tested for all three: RF, anti-CCP, and CRP (CPT 86140/86141) and/or ESR (CPT 85651/85652). The distinction matters. A negative RF and negative anti-CCP doesn't automatically disqualify the member — but all three markers must have been tested and documented.

Second, step therapy failure. Aetna requires documented failure of methotrexate (MTX) monotherapy at a maximum titrated dose of at least 15 mg per week over three months — or documented intolerance or contraindication to MTX. The policy then requires further documentation of inadequate response to combination therapy with hydroxychloroquine and/or sulfasalazine, intolerable adverse events, or contraindications to those agents.

This is layered step therapy with very specific documentation requirements. Moderate to high disease activity alone can satisfy the step therapy condition, but you still need the biomarker testing documented first.

Other Covered Indications

Beyond RA, Aetna's etanercept coverage policy extends to:

Each indication carries its own step therapy and documentation requirements. This post covers RA in depth because it's the highest-volume indication and the one with the most complex biomarker criteria. If you bill etanercept for plaque psoriasis or GvHD, pull the full CPB 0315 text for those indication-specific criteria before the effective date.

---

Coverage Indications at a Glance

---

Aetna Etanercept Billing Guidelines and Action Items 2026

The real risk here isn't complex criteria — it's documentation gaps. Aetna's billing guidelines for J1438 require precise clinical documentation matched to specific criteria. Here's what to do before January 5, 2026.

Copy Action Items

If your patient population includes a high volume of seronegative RA cases — patients with negative RF and negative anti-CCP — talk to your compliance officer before the effective date. The policy allows for seronegative RA approval if all three biomarkers (RF, anti-CCP, and CRP/ESR) were tested, but this path requires airtight documentation. Don't assume prior approvals under the old policy language will auto-renew under these criteria.

---

Aetna Etanercept Exclusions and Non-Covered Indications

CPB 0315 doesn't publish a flat exclusion list in the truncated summary available here, but the structure of the policy makes non-coverage clear by omission. If the indication isn't listed — and the prescriber doesn't match the specialty requirement for that indication — Aetna considers it not medically necessary.

The real-world claim denial risk comes from two gaps. First, off-label use outside the listed indications. Second, prescriber specialty mismatches — particularly plaque psoriasis billed under a rheumatologist rather than a dermatologist, or GvHD billed without oncologist or hematologist involvement.

For the full experimental and investigational designations under CPB 0315, review the complete policy at app.payerpolicy.org/p/aetna/0315. The policy references CD11c expression and DNA methylation as biomarkers of etanercept response — these appear in the code grouping labels and reflect investigational research context, not covered clinical testing under this policy.

---

CPT, HCPCS, and ICD-10 Codes for Etanercept Under CPB 0315

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J1438	HCPCS	Injection, etanercept, 25 mg